Immediate-release and extended-release DXM; additional ingredients in combination products.
Immediate and extended release
A modern description should name the formulation explicitly. DXM hydrobromide and polistirex have different profiles; absorption timing depends on the product and conditions.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: The Delsym label describes an extended-release polistirex suspension. The Auvelity label distinguishes immediate-release DXM from extended-release bupropion.
Limits of the conclusion: Read the active-ingredient amount on the label together with the stated salt and formulation. Assessing bromide requires the actual product composition.
Assessment should use the complete ingredient list. Antihistamines, acetaminophen and other components have their own risks, which depend on the substance and exposure.
Clarified
According to the 2026 audit · edition
Evidence and limitations
What was examined: Monte examines serotonin toxicity in overdose involving DXM and chlorpheniramine. Chyka’s guideline separately requires consideration of accompanying product ingredients.
Limits of the conclusion: A subjective plateau category offers little help in assessing toxicity of additional ingredients. Their names and amounts are needed.